Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Interest Expenses (2022 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Interest Expenses for 4 consecutive years, with $8.3 million as the latest value for Q4 2025.

  • Quarterly Interest Expenses rose 137.12% to $8.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.3 million through Dec 2025, up 52.05% year-over-year, with the annual reading at $22.3 million for FY2025, 52.06% up from the prior year.
  • Interest Expenses for Q4 2025 was $8.3 million at Madrigal Pharmaceuticals, up from $7.5 million in the prior quarter.
  • The five-year high for Interest Expenses was $8.3 million in Q4 2025, with the low at $780000.0 in Q2 2022.
  • Average Interest Expenses over 4 years is $3.6 million, with a median of $3.5 million recorded in 2024.
  • The sharpest move saw Interest Expenses soared 271.92% in 2023, then decreased 14.1% in 2025.
  • Over 4 years, Interest Expenses stood at $1.7 million in 2022, then surged by 136.09% to $4.0 million in 2023, then dropped by 11.89% to $3.5 million in 2024, then surged by 137.12% to $8.3 million in 2025.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $8.3 million, $7.5 million, and $3.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.